http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Grant of Restricted Stock Units and Warrants to Employees in Genmab
-
Genmab A/S (GMAB) Reports FY23 DARZALEX Sales of $9.74B
-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023
-
Genmab A/S (GMAB) Announces Decision in Arbitration Appeal under License Agreement with Janssen
-
Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen
-
Pfizer (PFE) and Genmab (GMAB) Reports TIVDAK sBLA Accepted for Priority Review by FDA
-
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
-
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
-
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
-
Genmab to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Genmab to Hold 2023 R&D Update and ASH Data Review Meeting
-
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
-
New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
-
Capital Increase in Genmab as a Result of Employee Warrant Exercise
-
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
-
Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
-
Major Shareholder Announcement
-
Genmab to Present at Jefferies London Healthcare Conference
-
Major Shareholder Announcement
-
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
-
Genmab A/S (GMAB) Reports Q3 Net DARZALEX Sales of $2.5B
-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
-
Grant of Restricted Stock Units and Warrants to Employees in Genmab
-
Genmab A/S (GMAB) Announces EPKINLY Approved by Japan Ministry of Health, Labour and Welfare
-
EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-C
-
Capital Increase in Genmab as a Result of Employee Warrant Exercise
-
Seagen (SGEN) and Genmab (GMAB) Report TIVDAK Met its Primary Endpoint of Improved Overall Survival
-
Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone
-
Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference
-
Capital Increase in Genmab as a Result of Employee Warrant Exercise
-
Genmab Updates 2023 Financial Guidance
-
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023
-
AbbVie (ABBV) and Genmab (GMAB) Report Positive Topline Results from Phase 1/2 EPCORE NHL-1 Trial
-
AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
-
Genmab A/S (GMAB) Announces Epcoritamab Added to National Comprehensive Cancer Network
-
Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’
-
Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’
-
Capital Increase in Genmab as a Result of Employee Warrant Exercise
-
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023
-
Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference
-
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
-
Transactions with Shares and Linked Securities in Genmab A/S Made By Managerial Employees and Their Closely Associated Persons
-
Capital Increase in Genmab as a Result of Employee Warrant Exercise
-
Genmab (GMAB) EPKINLY Approved by FDA as First and Only Bispecific Antibody to Treat Adults with R/R Diffuse Large B-cell Lymphoma
-
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (D
-
Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen
-
Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen
-
Genmab A/S (GMAB) Reports Q1 Net Sales of DARZALEX of $2.27B
-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023
